Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2018

View Archived Issues

Gene therapy for dominant blindness

Wee1 is a target in rhabdomyosarcoma

KW-6356 affects motor scores in phase II early Parkinson's disease trial

Liver-targeted prodrug may prove effective in fibrosis

DA-9701 may improve gastric motility in Parkinson's disease patients

Amgen targets the apelin receptor with AMG-986 for heart failure therapy

Lenvima approved in Europe as first-line treatment in adults with advanced or unresectable HCC

Toca 5 pivotal phase III study of Toca-511/Toca-FC continues without modification

Preclinical data and structure described for next-generation TYK2 inhibitor PF-06826647

GlaxoSmithKline presents leucine-rich repeat serine/threonine-protein kinase 2 inhibitors

Yangzhou Blue Biomedical Technology Co. patents penicilone derivatives

N-acetyl-beta-D-glucosaminidase inhibitors identified at Janssen

University of South Australia discloses cyclin-dependent kinase inhibitors

New selective Mcl-1 inhibitors with in vivo activity described by Vanderbilt University

DSMB completes new review of safety data from FOCUS trial of melphalan/HDS

FDA approves Takhzyro for prevention of HAE attacks

FDA approves Diacomit for seizures associated with Dravet syndrome

Telix submits CTA to begin phase III trial in Europe with TLX-250 for renal cancer imaging

FDA approves Inveltys for post-operative inflammation and pain

bluebird bio and Gritstone Oncology establish cancer cell therapy collaboration

FDA approves cobas EGFR Mutation Test v2 as companion diagnostic test with Iressa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...